RET and medullary thyroid gland carcinoma: In 2020, both the new generation TKIs, selpercatinib and pralsetinib, were granted FDA approval in patients with advanced RET-mutant MTC who require systemic therapy and indeed they are considered a highly potent treatment in patients with RET-driven MTCs (Subbiah et al. 2018a).